Drug Profile
OraPro-COVID-19 - iosBio
Alternative Names: COVID-19 vaccine - iosBioLatest Information Update: 01 Oct 2020
Price :
$50
*
At a glance
- Originator Stabilitech Biopharma
- Developer iosBio
- Class COVID-19 vaccines; Gene therapies; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 30 Sep 2020 Stabilitech Biopharma is now called iosBio
- 30 Sep 2020 Stabilitech Biopharma plans a clinical trial for COVID-19 infections in the US and Europe in first quarter of 2021
- 19 Mar 2020 OraPro-COVID-19 - Stabilitech Biopharma is available for licensing as of 22 Apr 2020. https://www.stabilitech.com/